Literature DB >> 22266666

Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients.

Ju-Yeh Yang1, Tsung-Chun Lee, Maria E Montez-Rath, Jane Paik, Glenn M Chertow, Manisha Desai, Wolfgang C Winkelmayer.   

Abstract

Impaired kidney function is a risk factor for upper gastrointestinal (GI) bleeding, an event associated with poor outcomes. The burden of upper GI bleeding and its effect on patients with ESRD are not well described. Using data from the US Renal Data System, we quantified the rates of occurrence of and associated 30-day mortality from acute, nonvariceal upper GI bleeding in patients undergoing dialysis; we used medical claims and previously validated algorithms where available. Overall, 948,345 patients contributed 2,296,323 patient-years for study. The occurrence rates for upper GI bleeding were 57 and 328 episodes per 1000 person-years according to stringent and lenient definitions of acute, nonvariceal upper GI bleeding, respectively. Unadjusted occurrence rates remained flat (stringent) or increased (lenient) from 1997 to 2008; after adjustment for sociodemographic characteristics and comorbid conditions, however, we found a significant decline for both definitions (linear approximation, 2.7% and 1.5% per year, respectively; P<0.001). In more recent years, patients had higher hematocrit levels before upper GI bleeding episodes and were more likely to receive blood transfusions during an episode. Overall 30-day mortality was 11.8%, which declined significantly over time (relative declines of 2.3% or 2.8% per year for the stringent and lenient definitions, respectively). In summary, despite declining trends worldwide, crude rates of acute, nonvariceal upper GI bleeding among patients undergoing dialysis have not decreased in the past 10 years. Although 30-day mortality related to upper GI bleeding declined, perhaps reflecting improvements in medical care, the burden on the ESRD population remains substantial.

Entities:  

Mesh:

Year:  2012        PMID: 22266666      PMCID: PMC3294302          DOI: 10.1681/ASN.2011070658

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  33 in total

1.  Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

Authors:  J P Kelly; D W Kaufman; J M Jurgelon; J Sheehan; R S Koff; S Shapiro
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

2.  Practical considerations on the use of the Charlson comorbidity index with administrative data bases.

Authors:  W D'Hoore; A Bouckaert; C Tilquin
Journal:  J Clin Epidemiol       Date:  1996-12       Impact factor: 6.437

3.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

Authors:  P S Romano; L L Roos; J G Jollis
Journal:  J Clin Epidemiol       Date:  1993-10       Impact factor: 6.437

4.  Risk of persistent or recurrent and intractable upper gastrointestinal bleeding in the era of therapeutic endoscopy.

Authors:  J P Terdiman; J W Ostroff
Journal:  Am J Gastroenterol       Date:  1997-10       Impact factor: 10.864

Review 5.  Risk factors of acute ulcer bleeding.

Authors:  M A Shafi; D E Fleischer
Journal:  Hepatogastroenterology       Date:  1999 Mar-Apr

6.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

7.  Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and practices between 1996 and 2000 in a multicentre French study.

Authors:  Frédéric Di Fiore; Stéphane Lecleire; Véronique Merle; Sophie Hervé; Christian Duhamel; Jean-Louis Dupas; Alain Vandewalle; Abdeslam Bental; Hervé Gouerou; Maryvonne Le Page; Michel Amouretti; Pierre Czernichow; Eric Lerebours
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-06       Impact factor: 2.566

8.  Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription.

Authors:  N S Abraham; D C Cohen; B Rivers; P Richardson
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

9.  Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia.

Authors:  N Chalasani; G Cotsonis; C M Wilcox
Journal:  Am J Gastroenterol       Date:  1996-11       Impact factor: 10.864

10.  Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients.

Authors:  Haimanot Wasse; Daniel L Gillen; Adrianne M Ball; Bryan R Kestenbaum; Stephen L Seliger; Donald Sherrard; Catherine O Stehman-Breen
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

View more
  33 in total

Review 1.  Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors:  Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

Review 2.  Use of proton pump inhibitors in dialysis patients: a double-edged sword?

Authors:  Geoffroy Desbuissons; Lucile Mercadal
Journal:  J Nephrol       Date:  2020-07-24       Impact factor: 3.902

3.  Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.

Authors:  Wolfgang C Winkelmayer; Benjamin A Goldstein; Aya A Mitani; Victoria Y Ding; Medha Airy; Sreedhar Mandayam; Tara I Chang; M Alan Brookhart; Steven Fishbane
Journal:  Am J Kidney Dis       Date:  2017-01-04       Impact factor: 8.860

4.  Heparin use in hemodialysis patients following gastrointestinal bleeding.

Authors:  Jenny I Shen; Aya A Mitani; Wolfgang C Winkelmayer
Journal:  Am J Nephrol       Date:  2014-10-17       Impact factor: 3.754

Review 5.  Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.

Authors:  Austin Hu; Jingbo Niu; Wolfgang C Winkelmayer
Journal:  Semin Nephrol       Date:  2018-11       Impact factor: 5.299

6.  Hemorrhage as a life-threatening complication after valve replacement in end-stage renal disease patients.

Authors:  Taro Nakatsu; Nobushige Tamura; Shigeki Yanagi; Shoichi Kyo; Takaaki Koshiji; Ryuzo Sakata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-04-19

7.  Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation.

Authors:  Jingwen Tan; Sunjae Bae; Jodi B Segal; Junya Zhu; G Caleb Alexander; Dorry L Segev; Mara McAdams-DeMarco
Journal:  Nephrology (Carlton)       Date:  2019-02       Impact factor: 2.506

8.  Upper Gastrointestinal Bleeding in Patients with End Stage Renal Disease: Causes, Characteristics and Factors Associated with Need for Endoscopic Therapeutic Intervention.

Authors:  Syed Mudassir Laeeq; Abbas Ali Tasneem; Farina M Hanif; Nasir Hassan Luck; Rajesh Mandhwani; Rajesh Wadhva
Journal:  J Transl Int Med       Date:  2017-06-30

Review 9.  Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?

Authors:  Jenny I Shen; Mintu P Turakhia; Wolfgang C Winkelmayer
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-11       Impact factor: 2.894

10.  Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS.

Authors:  Manish M Sood; Maria Larkina; Jyothi R Thumma; Francesca Tentori; Brenda W Gillespie; Shunichi Fukuhara; David C Mendelssohn; Kevin Chan; Patricia de Sequera; Paul Komenda; Claudio Rigatto; Bruce M Robinson
Journal:  Kidney Int       Date:  2013-05-15       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.